Study Assessing Azithromycin Treatment for Children Aged 3 to 17 Hospitalized with Critical Asthma

What this Trial Is About

Researchers are evaluating the effects of Azithromycin, an antibiotic, on the immune response in children aged 3 to 17 who are hospitalized with critical asthma, a severe asthma condition requiring intensive care. This study aims to understand how Azithromycin affects a specific inflammatory biomarker called periostin and to explore any differences in clinical outcomes and safety events related to this treatment compared to standard care without Azithromycin. Participants will be divided into two groups one receiving Azithromycin at a dose of 10 mgkg once daily up to 500 mg for 3 days alongside their usual care, and the other receiving standard care without Azithromycin. The study focuses on the short hospital period during which the children receive treatment and monitoring. Throughout the study, participants will have blood tests to measure periostin levels at 24, 48, and 72 hours after enrollment. Researchers will also track adverse events, length of hospital stay, use of asthma treatments, and carbon dioxide levels. Monitoring occurs primarily during approximately 3 days of hospitalization, with safety and efficacy outcomes assessed within this timeframe.

Azithromycin for Critical Asthma - Pediatrics